NPAT up 83.7% on $30.3m disposal gain as continuing PBT fell 43.5%

On the same statutory basis, profit before tax actually fell 43.5% to $27.1m, and operating profit from continuing operations fell to $34.3m. The release describes the continuing-operations EBIT decline as 29% versus FY22's record profit.

Revenue as shown in the like-for-like file falls 26.4% to $493.6m, but that comparison sets current continuing-operations revenue against the prior-year group total that still contained the divested Community Health business. Management's stated continuing-operations revenue growth is 3%.

Operating cash flow fell 30.3% to $45.9m, while the cash balance rose 28.9% to $58.2m, consistent with disposal proceeds landing on the balance sheet. Gross borrowings were broadly unchanged at $23.5m.

• Continuing operations contributed $20.3m of after-tax profit; the discontinued operation added $30.3m. Without that gain, NPAT would have fallen sharply versus the prior $24.6m. The headline 83.7% growth, the 11.1% NPAT payout ratio, and the lift in ROE to 22.4% from 14.1% are all flattered by a non-recurring item, which matters because none of these will repeat in FY24 on the same basis.

• Continuing operations show margin compression, not growth. With management citing 3% continuing-operations revenue growth, 10% script-volume growth, and 2% retail growth, a 29% drop in continuing EBIT points to cost or mix pressure rather than demand weakness. The dominant Pharmacy Services segment's segment result fell to $21.1m from $35.9m on largely flat revenue of $360.4m, isolating where the margin is being lost.

• Cash generation weakened in line with continuing earnings, not the headline. Operating cash flow fell 30.3% even as reported NPAT rose. FCF pre-lease at $40.2m versus $61.7m prior is the cleaner read on the period's economics, and capex stepped up to 1.2% of revenue from 0.6%, with inventory days lengthening by 6.1 to 23.6.

The HY23 to FY23 shape is also distorted: the first half captured 71.9% of full-year revenue but only 25.1% of full-year NPAT, because the disposal gain landed in the second half. That makes the implied second-half NPAT of $33.9m essentially a one-off-laden figure rather than an indication of underlying run-rate.

This means the release does not support a clean projection of FY24 earnings from FY23 reported numbers. The relevant anchor is continuing-operations EBIT of $34.3m, and whether the margin compression visible in Pharmacy Services is structural or transitional.

Roughly $30.3m of the $45.2m NPAT is a disposal-related gain. The continuing-operations PBT of $27.1m, down 43.5% on the stated comparator, is the cleaner read on operating performance, and the tax line is not the explanation: the effective tax rate fell only modestly to 25.1% from 29.7%, a small tailwind that does not move the underlying story.

Cash quality also weakened. FCF pre-lease covered only 88.9% of reported NPAT this year, against 251.3% in FY22, and operating cash flow fell more steeply than continuing earnings did. Inventory days rose to 23.6 from 17.5, absorbing working capital while receivable days improved to 10.1 from 16.9. The net cash position strengthened by $13.6m, but that improvement sits alongside disposal proceeds rather than being generated by continuing operations.

This briefing cannot assess whether the margin compression in continuing operations reflects temporary cost pressure or a structural shift in the pharmacy retail and services model.